Relationship between methylation and colonic inflammation in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10591-10598

  Lobatón, Triana ^a   Azuara, Daniel ^a   Rodríguez Moranta, Francisco ^a   Loayza, Carolina ^a   Sanjuan, Xavier ^a   De Oca, Javier ^a   Fernández Robles, Ana ^a   Guardiola, Jordi ^a   Capellá, Gabriel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Aberrant methylation; Colitis associated colorectal cancer; Colonic inflammation; Dysplasia; Inflammatory bowel disease

Indexed keywords

SLIT2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; NERVE PROTEIN; SIGNAL PEPTIDE; SLIT HOMOLOG 2 PROTEIN; TGFB2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; CLINICAL ARTICLE; COLON BIOPSY; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DESCENDING COLON; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PROMOTER REGION; REMISSION; ULCERATIVE COLITIS; AGED; BIOPSY; CHI SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; COLON; GENETICS; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; CROHN DISEASE; DNA METHYLATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE TISSUE PROTEINS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA2; TREATMENT OUTCOME;

EID: 84920599060     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10591     Document Type: Article

References (45)

1. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381.e1; quiz e13-14 [PMID: 22522090 DOI: 10.1053/j.gastro.2012.04.016]
2. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143: 382-389 [PMID: 22609382 DOI: 10.1053/j.gastro.2012.04.054]
3. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009; 6: 297-305 [PMID: 19404270 DOI: 10.1038/nrgastro.2009.44]
4. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7-G17 [PMID: 15194558 DOI: 10.1152/ajpgi.00079.2004]
5. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence- based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-990 [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003]
6. Kiesslich R, Neurath MF. Chromoendoscopy in inflammatory bowel disease. Gastroenterol Clin North Am 2012; 41: 291-302 [PMID: 22500518 DOI: 10.1016/j.gtc.2012.01.016]
7. Fujii S, Katsumata D, Fujimori T. Limits of diagnosis and molecular markers for early detection of ulcerative colitisassociated colorectal neoplasia. Digestion 2008; 77 Suppl 1: 2-12 [PMID: 18204256 DOI: 10.1159/000111482]
8. Melville DM, Jass JR, Morson BC, Pollock DJ, Richman PI, Shepherd NA, Ritchie JK, Love SB, Lennard-Jones JE. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989; 20: 1008-1014 [PMID: 2793156]
9. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459 [PMID: 14762782 DOI: 10.1053/j.gastro.2003.11.010]
10. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816 [PMID: 21530747 DOI: 10.1053/j.gastro.2011.01.057]
11. Mathy C, Schneider K, Chen YY, Varma M, Terdiman JP, Mahadevan U. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003; 9: 351-355 [PMID: 14671483 DOI: 10.1097/0005472 5-200311000-00002]
12. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105; quiz 1340-1341 [PMID: 17919486 DOI: 10.1053/j.gastro.2007.08.001]
13. Thorsteinsdottir S, Gudjonsson T, Nielsen OH, Vainer B, Seidelin JB. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat Rev Gastroenterol Hepatol 2011; 8: 395-404 [PMID: 21647200 DOI: 10.1038/nrgastro.2011.96]
14. Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 2012; 33: 723-731 [PMID: 22235026 DOI: 10.1093/carcin/bgs006]
15. Sanchez JA, Dejulius KL, Bronner M, Church JM, Kalady MF. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Inflamm Bowel Dis 2011; 17: 1966-1970 [PMID: 21618350 DOI: 10.1002/ibd.21526]
16. Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2010; 105: 1610-1619 [PMID: 20160714 DOI: 10.1038/ajg.2010.22]
17. Olaru AV, Cheng Y, Agarwal R, Yang J, David S, Abraham JM, Yu W, Kwon JH, Lazarev M, Brant SR, Marohn MR, Hutcheon DF, Harpaz N, Meltzer SJ, Mori Y. Unique patterns of CpG island methylation in inflammatory bowel diseaseassociated colorectal cancers. Inflamm Bowel Dis 2012; 18: 641-648 [PMID: 21830278 DOI: 10.1002/ibd.21826]
18. Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitisassociated neoplasias. Gastroenterology 2007; 132: 1254-1260 [PMID: 17408633 DOI: 10.1053/j.gastro.2007.01.035]
19. Goel GA, Kandiel A, Achkar JP, Lashner B. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol 2011; 106: 719-730 [PMID: 21386829 DOI: 10.1038/ajg.2011.51]
20. Shin CM, Kim N, Park JH, Kang GH, Kim JS, Jung HC, Song IS. Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae. J Pathol 2012; 226: 654-665 [PMID: 22252584 DOI: 10.1002/path.2990]
21. Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, Oda I, Gotoda T, Ushijima T. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol 2010; 45: 37-44 [PMID: 19821005 DOI: 10.1007/s00535-009-0142-7]
22. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin- 6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 2006; 66: 10517-10524 [PMID: 17079474 DOI: 10.1158/0008-5472]
23. Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari MJ, Yu Y, Montagna C, Montgomery EA, Canto M, Dunbar KB, Wang J, Roa JC, Mo Y, Bhagat T, Ramesh KH, Cannizzaro L, Mollenhauer J, Thompson RF, Suzuki M, Meltzer SJ, Melnick A, Greally JM, Maitra A, Verma A. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 2011; 7: e1001356 [PMID: 21483804 DOI: 10.1371/journal. pgen.1001356]
24. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49 [PMID: 19955394 DOI: 10.1093/carcin/bgp272]
25. Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Wilson KT, James SP, Herman JG, Meltzer SJ. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000; 60: 4864-4868 [PMID: 10987299]
26. Saito S, Kato J, Hiraoka S, Horii J, Suzuki H, Higashi R, Kaji E, Kondo Y, Yamamoto K. DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis 2011; 17: 1955-1965 [PMID: 21830274 DOI: 10.1002/ibd.21573]
27. Azuara D, Rodriguez-Moranta F, de Oca J, Sanjuan X, Guardiola J, Lobaton T, Wang A, Boadas J, Piqueras M, Monfort D, Galter S, Esteller M, Moreno V, Capellá G. Novel methylation panel for the early detection of neoplasia in highrisk ulcerative colitis and Crohn's colitis patients. Inflamm Bowel Dis 2013; 19: 165-173 [PMID: 22532293 DOI: 10.1002/ibd.22994]
28. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35: 950-954 [PMID: 8063223]
29. Goldstone R, Itzkowitz S, Harpaz N, Ullman T. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. Gastrointest Endosc 2011; 74: 1087-1093 [PMID: 21907984 DOI: 10.1016/j.gie.2011.06.028]
30. Goldstone R, Itzkowitz S, Harpaz N, Ullman T. Dysplasia is more common in the distal than proximal colon in ulcerative colitis surveillance. Inflamm Bowel Dis 2012; 18: 832-837 [PMID: 21739534 DOI: 10.1002/ibd.21809]
31. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7: 982-1018 [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016]
32. Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57: 1246-1251 [PMID: 18337322 DOI: 10.1136/gut.2007.143453]
33. Lobatón T, Rodríguez-Moranta F, Lopez A, Sánchez E, Rodríguez- Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1034-1042 [PMID: 23470502 DOI: 10.1097/MIB.0b013e3182802b6e]
34. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786 [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038]
35. Puig P, Urgell E, Capellá G, Sancho FJ, Pujol J, Boadas J, Farré A, Lluís F, González-Sastre F, Mora J. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer 2000; 85: 73-77 [PMID: 10585586]
36. Puig P, Urgell E, Capellá G, Villanueva A, Grau M, Sancho FJ, Pujol J, Lluís F, González-Sastre F, Mora J. Improved detection of K-ras codon 12 mutations in fecal exfoliated cells. Lab Invest 1999; 79: 617-618 [PMID: 10334573]
37. Azuara D, Rodriguez-Moranta F, de Oca J, Soriano-Izquierdo A, Mora J, Guardiola J, Biondo S, Blanco I, Peinado MA, Moreno V, Esteller M, Capellá G. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer 2010; 9: 168-176 [PMID: 20643622 DOI: 10.3816/CCC.2010.n.023]
38. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard- Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-537 [PMID: 6979471]
39. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956; 1: 1315-1318 [PMID: 13316140]
40. Florén CH, Benoni C, Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22: 459-462 [PMID: 3602926]
41. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47: 404-409 [PMID: 10940279 DOI: 10.1136/gut.47.3.404]
42. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic find- ings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-95 [PMID: 3949241]
43. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-178 [PMID: 1864537]
44. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, Chu FF, Pfeifer GP. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 2008; 68: 10280-10289 [PMID: 19074896 DOI: 10.1158/0008-5472.CAN-08-1957]
45. Katsurano M, Niwa T, Yasui Y, Shigematsu Y, Yamashita S, Takeshima H, Lee MS, Kim YJ, Tanaka T, Ushijima T. Earlystage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. Oncogene 2012; 31: 342-351 [PMID: 21685942 DOI: 10.1038/onc.2011.241]